About ubs-ch

This author has not yet filled in any details.
So far ubs-ch has created 398 blog entries.

Weekly Hits: Mergers and acquisitions & Netflix

KeyInvest Weekly Hits

Friday, 25.01.2019

  • Topic 1: Mergers and acquisitions - Systematic premium hunting
  • Topic 2: Netflix - Performing well

Mergers and acquisitions
Systematic premium hunting

In the Swiss mergers and acquisitions (M&A) market, 2019 began with a bang: On January 16, the logistics group DSV made a non-binding offer for Panalpina. The Danes indicated that they were prepared to pay CHF 170 in cash in addition to treasury shares for each share in the company. The price offered thus represented a premium of 24.1% over the closing price fixed for Panalpina on the day prior to publication.¹ This is yet another example of how lucrative M&A events can be for investors. With Open End PERLES (symbol: MANDAU) on the Solactive M&A Europa Total Return Index, it is possible to systematically hunt for acquisition premiums. The participation product replicates the 40 potential takeover candidates in the benchmark with a subscription ratio of 1:1.

It is clear that some investors are betting on there being further bidders for Panalpina. In any case, one week after the approach by DSV, the logistics company’s shares have been trading almost seven francs higher than the offer price. One potential counterbidder would be Kühne+Nagel. The Swiss sector player already signaled its interest in Panalpina last autumn. In response to an inquiry from Reuters, Kühne+Nagel did not wish to comment on the latest developments, however. (Source: Thomson Reuters media report, 1/16/2019).

Nevertheless, DSV’s approach for the Swiss mid-cap company underlines just how active the Swiss M&A market is. According to a recent study by the consulting and audit company KPMG, the number of deals over the last year rose by 24.8% to 493, which is the highest number since the survey began in 2007. In terms of transaction volumes, the experts have observed above-average growth: This figure increased by 30.9% to USD 101.5 billion, which is still somewhat short of the record USD 188.1 billion from 2014. The largest deal of the year involved an SMI™ heavyweight: Novartis sold a 36.5% stake in a joint venture to GlaxoSmithKline for USD 13 billion. (Source: KPMG, press release, January 16, 2019)
The only Swiss company currently in the M&A Europe Index also comes from the same sector as these two major corporations. Vifor Pharma is one of a total of 40 shares to have currently made it through the multi-level selection process. The first criteria stipulated by the index methodology relate to trading liquidity and market capitalization. All shares that meet these quantitative requirements are then subjected to checks using well-known stock market indicators. In addition to the average analysts’ forecast regarding earnings per share for the upcoming fiscal year (FY1 IBES EPS), the price-to-book value (PBV) ratio and the one-year revenue growth must be positive.
Stocks that are overvalued in terms of PBV compared to their sector are not included. The same applies to companies whose average EPS estimate is below the sector median. Of the remaining stocks, the 40 companies with the strongest revenue growth are taken into the index with equal weightings. Each quarter, Solactive carries out a review and makes adjustments as necessary – this process involves restoring the 40 component stocks to equal weightings.

Opportunities: All it takes is a single order to make this dynamic, Europe-focused M&A strategy part of your portfolio with Open End PERLES (symbol: MANDAU). The product passively replicates the underlying assets without any maturity limitation after deduction of the annual management fee of 0.75% p.a. It allows investors to participate in the distributions from the shares contained in the index – any net dividends are reinvested in the benchmark.

Risks: Open End PERLES do not have capital protection. Losses will be made if the underlying index declines. The currency risk must also be taken into account, as the trading currency of some index constituents may differ from the trading currency of the certificate shown. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Solactive M&A Europe TR Index vs. EURO STOXX 50™ TR Index
(5 years; for illustrative purposes only; figures in %)

In the wake of the recent stock market correction, the M&A benchmark lost its long-term advantage over the EURO STOXX 50™. However, it was able to make up some ground at the start of 2019.

Source: UBS AG, Bloomberg

As of 23.01.2019

Solactive M&A Europe TR Index: Weighting by country

French companies in the Solactive M&A Europa TR Index are currently setting the tone. German and UK shares are the only others to account for double-digit percentage weightings.

Source: UBS AG, Bloomberg

As of: 23.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

Open End PERLES on Solactive M&A Europe Total Return Index

Symbol MANDAU
SVSP Name Tracker Certificates
SPVSP Code 1300
Underlying Solactive M&A Europe Total Return Index
Currency EUR
Ratio 1:1
Administration fee 0.75% p.a.
Expiry Open End
Participation 100%
Issuer UBS AG, London
Bid/Ask EUR 176.20 / 178.00
 
Termsheet

Key facts Solactive M&A Europe Total Return Index

ISIN DE000SLA16H5
Index Sponsor Solactive AG
Index Currency
 EUR
Index Components 40
Dividend Reinvest (Total Return Index)
Coupon 14.00% p.a.
Current status
 182.10
Underlying / date 100 / 01.03.2010
Issuer UBS AG, London
Subscription until 30.01.2019, 15:00 h
 
More information

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 23.01.2019

Market overview

Index Quotation Week¹
SMI™ 8’957.19 0.9%
SLI™ 1’390.66 1.2%
S&P 500™ 2’638.70 0.9%
Euro STOXX 50™ 3’112.13 1.1%
S&P™ BRIC 40 4’025.73 0.3%
CMCI™ Compos. 896.53 0.4%
Gold (troy ounce) 1’284.00 USD -0.8%

¹ Change based on the closing price of the previous day compared to the closing price a week ago.

SMI™ vs. VSMI™ 1 year

smi vs vsmi

The VSMI™ Index is calculated since 2005. It shows the volatility of the stocks within the SMI™ index. A portfolio which reacts only to changes in volatility instead of volatility itself is relevant for the calculation. Thereby, the VSMI™ methodology uses the squared volatility, known as variance, of the SMI options with remaining time to expiry of 30 days traded at the Eurex.

Source: UBS AG, Bloomberg

As of: 23.01.2019

Netflix
Performing well

The Netflix share price is once again keeping Wall Street on its toes. Since the start of the year, the streaming service provider has gained 26%, helping it to further build on its long-term lead over the NASDAQ-100 Index (see chart)¹. Even if the technology high-flyer does not maintain this pace, a minimum return of almost 16% would be possible with Kick-In GOAL (symbol: KCEFDU). At present, the underlying stock is 37% away from the barrier.

Netflix has been disrupting the media sector for many years. Now the streaming service provider also has its eyes on the greatest film awards in the world. The Netflix production “Roma” has received ten nominations for this year’s Oscars, including in the “Best Film” category. If it were to actually win this coveted prize, this would be yet another key milestone for Netflix. (Source: Thomson Reuters media report, January 22, 2019).

In operational terms, the company continued to grow in 2018. In the fourth quarter alone, Netflix attracted 8.8 million new customers – more than in any other previous quarter. The company now has 139 million subscribers. By contrast, Wall Street was less impressed with its outlook. For the ongoing first quarter, the company’s management are expecting revenues of almost USD 4.5 billion, with a profit of USD 253 million. This forecast is significantly below previous analyst expectations. In light of this, the euphoria surrounding the Nasdaq share, which was sparked by the announcement of price increases, abated somewhat. (Source: Thomson Reuters media report, January 18, 2019).

Opportunities: Although Kick-In GOAL (symbol: KCEFDU) was able to make up some ground following the recent price rally by Netflix, the structured product is trading some way below the 100% mark. This means there is a return opportunity, which is somewhat larger than the coupon. On maturity, there is the prospect of income amounting to 20% p.a. for Kick-In GOAL. This requires that Netflix does not fall to or below the barrier of USD 208.566. At present, the underlying stock has a safety buffer of 36.6%

Risks: This product does not have capital protection. If Netflix falls to or below the kick-in level (barrier) once during the term, the underlying stock has to be trading at least at the strike level on maturity. Otherwise, the amount repaid will fall in line with the decline in the Netflix share price. In this case, it is likely that losses will be incurred. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Netflix vs. Nasdaq-100 Index
(five years, for illustrative purposes only, figures in %)¹

Source: UBS AG, Bloomberg

As of: 23.01.2019

10.00% p.a. Kick-In GOAL on Netflix

Symbol KCEFDU
SVSP Name Barrier Reverse Convertibles
SPVSP Code 1230
Underlyings Netflix
Currency USD
Coupon 10.00% p.a.
Sideways return 13.93% (18.02% p.a.)
Kick-In Level (Distance)
 USD 208.566 (35.56%)
Expiry 07.11.2019
Issuer UBS AG, London
Bid/Ask 93.14% / 94.14%
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 23.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Mergers and acquisitions & Netflix2019-02-15T12:08:16+01:00

Die Politik gibt weiterhin den Ton an

KeyInvest Blog

21. Januar 2019 – UBS Wochenkommentar Rück-/Ausblick

Die Politik gibt weiterhin den Ton an

Noch immer übertönt das politische Gepolter alles andere. Brexit, Handelskrieg, ein Government Shutdown – die Themen bleiben im Wesentlichen die gleichen. Doch anders als noch vor ein paar Wochen, scheint das Gehör der Investoren nachzulassen. Hätte das Scheitern des Brexit-Deals, wie am vergangenen Mittwoch geschehen, im Dezember die Kurse höchstwahrscheinlich noch unter Druck gesetzt, legten sie nun sogar leicht zu.

Grossbritannien bleibt zwar auch in der neuen Woche auf der Agenda, Premierministerin Theresa May wird nun einige Änderungen an ihrem Abkommen mit der EU vornehmen und diese präsentieren (nach Radaktionsschluss). Doch wie immer sie auch ausfallen werden, die aktuelle Stimmung an den Börsen zeigt, dass die Anlegergemeinde weiterhin auf einen «weichen Brexit» hofft. Interessant könnte es sowohl aus politischer wie auch aus wirtschaftlicher Sicht zudem vom 22. bis 25. Januar werden. Dann versammeln sich im Schweizer Bergort Davos wieder führende Politiker, Wirtschaftsexperten und Unternehmenslenker aus aller Welt auf dem 48. Weltwirtschaftsforum. Hochrangige Staatsmänner wie US-Präsident Donald Trump sowie der chinesische Staatschef Xi Jinping sind allerdings nicht mit von der Partie.

Die Banken im Visier

Der Fokus der Märkte wechselt trotz aller politischer Ereignisse derzeit wieder verstärkt von der Makro- zur Mikroökonomie. Denn die Unternehmen haben bereits damit begonnen, ihre Bücher für das abgelaufene Geschäftsjahr zu öffnen. Die Vorreiter waren die US-Banken. Und diese glänzten zum Teil mit Rekordergebnissen – der US-Unternehmenssteuer sei Dank. So zum Beispiel die Bank of America. Die zweitgrösste Bank der USA steigerte ihren Gewinn im vierten Quartal um mehr als das Dreifache auf 7,3 Milliarden Dollar. Doch auch ohne Sondereffekte der Steuerreform läge das Plus bei beachtlichen 39 Prozent. Ebenfalls positiv überraschen konnten Goldman Sachs, die Citigroup und JP Morgan.

Ob das ein gutes Omen für die europäische Geldhäuser ist, wird sich schon bald zeigen. Am 22. Januar eröffnet die UBS die Bilanzsaison der Schweizer Banken, am 1. Februar zieht die Deutsche Bank nach und am 14. Februar wird die Credit Suisse zusammen mit der Commerzbank ihre Bücher offenlegen. Die guten Berichte aus den USA sorgten auch bei hiesigen Valoren zuletzt für Kursaufschläge. Mit prozentual zweistelligen Gewinnen befinden sich Julius Bär und Credit Suisse unter den Top drei im SMI seit Silvester.

Im Aufwärtstrend

Dass die Bank-Aktien generell derzeit auf Outperformance-Kurs, zeigt sich mit Blick auf den Sektor-Index. Während der STOXX Europe 600 in diesem Jahr um 3,2 Prozent avancierte, bewegte sich der STOXX Europe 600 Banks knapp doppelt so schnell nach oben.1 (Stand: 18.01.2019) Damit versucht die Branche das Gap zum Gesamtmarkt, das sich auf knapp 20 Prozentpunkte auf Sicht von einem Jahr beläuft, etwas zu schliessen (siehe Chart). Wer mittelfristig höhere Kurse bei den Finanztiteln erwartet, für den könnte der ETT (Symbol: ETBAN) auf den STOXX Europe 600 Banks EUR Net Return Index. Das Produkt bietet eine 1:1-Partizipation und kommt aktuell ohne jährliche Verwaltungsgebühr aus.2

SMI-Konzerne öffnen ihre Bücher

Die «Earnings Season» hierzulande im Blue Chip-Segment hat bereits Richemont eröffnet. Anders als das Gros der Konzerne berichtete der Luxusgüterkonzern nicht über das vierte Quartal, sondern aufgrund seines gebrochenen Geschäftsjahres über das dritte. Wie dem auch sein, letzten Endes setzte Richemont mit insgesamt 3,92 Milliarden Euro ein Viertel mehr um als im Vorjahr und konnte die Erwartungen der Analysten schlagen. Gewinnzahlen wird der Uhren- und Schmuckverkäufer erst wieder im Mai bei der Präsentation der Jahresbilanz veröffentlichen.

Einen knappen Einblick in den Geschäftsverkauf gestattete auch Geberit. Der Sanitärtechnikkonzern steigerte seine Erlöse im vergangenen Jahr um knapp sechs Prozent auf 3,1 Milliarden Franken. Damit wurde erstmals in der Geschichte des Unternehmens die Drei-Milliarden-Grenze passiert. Die Ebitda-Marge lag voraussichtlich bei 28 Prozent und somit in etwa auf dem Vorjahresniveau. Mit der Entwicklung konnte der Sanitärspezialist die Markterwartungen erfüllen. Das komplette Zahlenwerk wird Geberit am 12. März vorstellen. Damit ist der Start in die Bilanzsaison in der Schweiz bereits gelungen. Die kommenden Tage werden zeigen, ob sich die positive Entwicklung auch fortsetzen kann. Nachfolgend haben wir Ihnen die noch im Januar anstehenden Termine der SMI-Mitglieder übersichtlich aufbereitet.

Wichtige Unternehmenstermine SMI-Mitglieder im Januar

Datum Bilanzvorlage 2019
22.01.2019 UBS
22.01.2019 SGS
25.01.2019 Givaudan
30.01.2019 Novartis
30.01.2019 Lonza
31.01.2019 Roche

Quelle: Thomson Reuters

STOXX Europe 600 Banks Index vs. STOXX Europe 600 Index

1) Bitte beachten Sie, dass vergangene Wertentwicklungen keine Indikationen für künftige Wertentwicklungen sind.
2) Die Konditionen der ETTs werden jährlich überprüft und können mit einer Frist von 13 Monaten nach Bekanntgabe angepasst werden.

Weitere Blogeinträge:

Fussball, Glühwein und Feiertage

Die Vorweihnachtszeit hält langsam aber sicher Einzug. In mehreren Schweizer Städten, darunter St. Gallen, Basel und Zürich, beginnen am 24. November die Weihnachtsmärkte. Diese beliebten Anlässe bieten eine gute Gelegenheit, um das Jahr Revue passieren zu lassen.

Unterschiedliche Taktgeber

In der vergangenen Woche blieb kein Börsenauge trocken. In der ersten Hälfte dominierten noch die Bären das Geschehen. Auf der einen Seite trieben drohende neue Lockdowns in China den Investoren Sorgenfalten auf die Stirn.

Ein Wechselbad der Gefühle

Gerade einmal 23 Zeilen umfasst das von der US-Notenbank am 2. November 2022 veröffentlichte geldpolitische Statement. Dieser kurze Text reichte, um die Börsen – quer durch die Anlageklassen – in Aufruhr zu versetzen. Während die Aktienkurse an der Wall Street nach unten drehten, wertete der US-Dollar deutlich auf.

Die Politik gibt weiterhin den Ton an2019-01-21T10:19:35+01:00

Weekly Hits: Or, Airbus & Boeing

KeyInvest Weekly Hits

Vendredi, 18.01.2019

  • Thème 1: Or - Un besoin de sécurité accru
  • Thème 2: Airbus / Boeing - Un duel transatlantique

Or
Un besoin de sécurité accru

La Chambre basse britannique a rejeté l’accord de sortie de l’UE négocié par la première ministre Theresa May avec Bruxelles. Bien que la cheffe du gouvernement travaille désormais à un « plan B », le risque d’un Brexit sans accord a augmenté. Il n’est donc pas étonnant que les investisseurs se retournent davantage vers la monnaie de crise qu’est l’or (l’or a augmenté de 3,7% depuis le 10 décembre 2018).¹ L’ETC (symbole CGCCIU) offre un accès transparent et efficace à l’important métal précieux. Le produit participe à l’identique à l’évolution de l’indice UBS Bloomberg CMCI Gold CHF Monthly Hedged TR. Les bénéficiaires de la hausse des prix de l’or sont notamment des producteurs de métal précieux comme Kinross Gold, FreeportMcRoRan et Barrick Gold. Ce trio constitue la base d’un Early Redemption (ER) Kick-In GOAL (symbole : KDAIDU). Avec le produit en souscription, les investisseurs peuvent prévoir un versement ferme de coupon d’un montant de 14,00% p.a. Par ailleurs, les trois actions très sensibles aux fluctuations débutent la période avec des barrières basses de 50% du niveau de cours d’origine.

Si seuls 202 députés ont approuvé l’accord de Brexit, une nette majorité de 432 parlementaires l’ont rejeté. Toutefois, Theresa May a relevé le défi du vote de la Chambre basse et annoncé un plan pour la procédure ultérieure. Il est possible que les choses s’arrêtent avant, car le leader de l’opposition Jeremy Corbyn a annoncé le dépôt d’une motion de défiance. (Source : Thomson Reuters, article de presse, 16.01.2019). Comme toujours, tout d’abord, le prix de l’or n’a que très faiblement réagi à la défaite fracassante du gouvernement britannique. Toutefois, le prix de l’once fine avait nettement augmenté en amont. Sur trois mois, le principal métal précieux a gagné 6 ;1% de sa valeur.¹ En plus des turbulences liées au Brexit, le conflit douanier entre les Etats-Unis et la Chine a incité les investisseurs à viser la valeur refuge.

D’autant plus que ce désaccord non résolu se répercute toujours davantage sur l’économie réelle. Par exemple, pour décembre, la Chine a annoncé un recul de 7,6% des importations par rapport à l’année précédente. Dans le même temps, les exportations ont diminué de 4,4%. Les analystes prévoyaient une croissance de ces deux chiffres repère. (Source : Thomson Reuters, article de presse, 15.01.2019).
Les actions du secteur minier se sont signalées suite à la hausse des prix du métal précieux. Par ailleurs, le secteur a attiré l’attention par une reprise : le groupe américain Newmont Mining rachète son concurrent canadien Goldcorp pour dix milliards de dollars US. Si l’accord est réellement conclu, ce sera la naissance de la plus grande entreprise aurifère du monde. En septembre 2018, Barrick Gold s’était emparée de Randgold Ressources. Cette acquisition a atteint un volume de 6,1 milliards de dollars US. (Source : Thomson Reuters, article de presse, 14.01.2019).

Opportunités: avec l’ETC (symbole : CGCCIU) sur l’indice UBS Bloomberg CMCI Gold CHF Monthly Hedged TR, les investisseurs peuvent intégrer simplement et à bon compte cette monnaie de crise à leur portefeuille. Le sous-jacent et le produit sont libellés en francs suisses. Les fluctuations de la valeur locale par rapport à la monnaie des matières premières qu’est le dollar sont couvertes sur une base mensuelle. L’Early Redemption Kick-In GOAL (symbole : KDAIDU) sur Kinross Gold, FreeportMcMoRan et Barrick Gold offre un positionnement avec couverture partielle dans le secteur minier. Tant qu’aucun sous-jacent n’atteint la barrière de 50% ou ne passe en-dessous pendant la période, le produit générera un rendement de 14,00% p.a. à l’échéance. Il est possible que les investisseurs touchent ce rendement par anticipation. Avec la fonction « Early Redemption », une échéance anticipée est possible.

Risques: les produits présentés n’offrent pas de protection du capital. Il peut y avoir des pertes avec l’ETC lorsque l’indice sous-jacent baisse. Si, pendant la durée de l’investissement, un des sous-jacents de l’ER Kick-In GOAL atteint une seule fois sa barrière respective (« Kick-In Level ») ou est inférieur à celle-ci, et que la fonction de remboursement anticipé ne s’applique pas, le montant remboursé en espèces à maturité par amortissement est basé sur la performance la plus faible (base Strike) des sous-jacents (au maximum toutefois à la valeur nominale majorée du coupon). Dans un tel cas, des pertes sont probables. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur. Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Or (dollars US par once fine) 5 ans¹

Depuis environ trois ans, la tendance est à une forte hausse pour l’or. L’once fine est ainsi passée par de fortes fluctuations pour arriver de moins de 1100 dollars US à récemment tout juste 1300 dollars US.

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

Kinross Gold vs. Freeport-McMoRan vs. Barrick Gold
(5 ans, aux fins d’illustration uniquement, données en %)¹

Le secteur aurifère a connu des moments assez difficiles auprès des investisseurs au cours des dernières années. Mais les cours de Kinross Gold, Freeport-McMoRan et Barrick Gold se sont quelque peu stabilisés.

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

ETC sur UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index

Symbol CGCCIU
SVSP Name Tracker Certifikat
SPVSP Code 1300
Sous-jacent UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index
Devise CHF
Rapport de souscription 10:1
Frais de gestion 0.38% p.a.
Participation 100%
Echéance Open End
Émetteur UBS AG, London
Bid/Ask CHF 77.70 / 78.05
 
Termsheet

14.00% p.a. Early Redemption Worst of Kick-In GOAL sur Kinross Gold / FreeportMcRoran / Goldstone

Symbol KDAIDU
SVSP Name Barrier Reverse Convertible
SPVSP Code 1230 (Auto-Callable)
Sous-jacent Kinross Gold / Freeport-McMoRan / Barrick Gold
Devise USD
Coupon 14.00% p.a.
Kick-In Level 50%
Echéance 30.01.2020
Émetteur UBS AG, London
Date de fixation du prix 30.01.2019, 15:00 h
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

Apérçu du marché

Index Citation Semaine¹
SMI™ 8’873.77 2.1%
SLI™ 1’374.48 2.4%
S&P 500™ 2’616.10 1.2%
Euro STOXX 50™ 3’077.22 0.2%
S&P™ BRIC 40 4’012.62 1.0%
CMCI™ Compos. 893.02 -0.2%
Gold (troy ounce) 1’293.80 USD 0.1%

¹ Changement basé sur le cours de clôture du jour précédent par rapport au cours de clôture de la semaine dernière.

SMI™ vs. VSMI™ 1 année

L’index VSMI™ est calculé depuis 2005. Il affiche la volatilité des actions inclus dans le SMI™ index. Pour la calculation, un portefeuille est utilisé qui ne réagit qu’au variations de la volatilité au lieu des variations des prix. En le faisant, la méthodologie du VSMI™ utilise la volatilité carré, connu sous le terme variance, des options sur le SMI avec 30 jours jusqu’à l’échéance négociées à la Bourse Eurex.

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

Airbus / Boeing
Un duel transatlantique

L’année était à peine terminée que les deux plus grands constructeurs d’avion du monde présentaient déjà leurs bilans opérationnels. Boeing a livré en 2018 un total de 806 appareils, se classant ainsi tout juste devant Airbus. Son rival a livré 800 avions à des compagnies aériennes et de leasing. En bourse également, en 2018, Boeing avait une longueur d’avance. Le titre du Dow Jones™ a ainsi renforcé son avance durable sur Airbus (cf. graphique).¹ Avec le nouvel Early Redemption (ER) Kick-In GOAL (symbole : KCZHDU), les investisseurs misent sur le fait que les deux grandes capitalisations pourront maintenir leurs cours plafonds ou qu’elles ne connaîtront du moins pas de trop fortes turbulences pendant la période : le coupon de 9,00% p.a. est associé à une marge de sécurité de 40%.

Avec une dernière ligne droite très performante en 2018, Airbus a réussi à réaliser très précisément les objectifs de livraison que la compagnie s’était fixés pour l’année. Des problèmes de livraison de moteurs au cours des mois précédents avaient éveillé des inquiétudes quant à la réalisation des prévisions. Mais en dépit de tous les cris d’orfraie du groupe européen, le groupe a enregistré une progression des livraisons pour la 16e année consécutive. Avec une croissance de 11% par rapport à la période précédente, Airbus a enregistré par ailleurs une nouvelle année record en 2018. Pendant ce temps, le nombre de nouvelles commandes baissait. L’entreprise a enregistré 747 commandes contre 1109 l’année précédente. Malgré tout, à la fin 2018, un carnet de commandes record de 7577 machines commerciales subsistait. (Source : Airbus, communiqué de presse, 09.01.2019)

Avec 806 jets livrés, Boeing a réalisé en 2018 un nouveau record. Le groupe de Seattle a ainsi progressé de 5,6% par rapport à l’année dernière. Dans le même temps, l’entreprise a enregistré des commandes pour 893 avions et une valeur totale de 143,7 milliards de dollars US. Le hit des ventes de Boeing reste le 737 MAX. Pour cette gamme de modèles, 675 commandes ont été enregistrées en 2018. En décembre, le programme a franchi le mur du son de 5000 commandes au total. (Source : Boeing, communiqué de presse, 08.01.2019)

Opportunités: UBS réunit comme sous-jacents dans un ER Kick-In GOAL (symbole : KCZHDU) les constructeurs d’avions classés sous « Buy » par la recherche interne. Le duo permet un coupon de 9,00% p.a. Une barrière de 60% du niveau initial s’oppose à cette opportunité de rendement. Compte tenu de la fonction « Early Redemption », il existe une opportunité d’obtenir le rendement maximal de manière anticipée. Condition : Les deux actions sont cotées au niveau du cours de début ou à un niveau supérieur à l’un des jours fixés.

Risques: il n’existe aucune protection du capital pour le produit présenté. Si, pendant la durée de l’investissement, l’un des sous-jacents atteint une seule fois la barrière respective (« Kick-In Level ») ou est inférieur à celle-ci, et que la fonction de remboursement anticipé ne s’applique pas, le remboursement par amortissement en espèces à l’échéance est basé sur la performance la plus faible (base Strike) du duo (au maximum toutefois à la valeur nominale majorée du coupon). Dans un tel cas, des pertes sont probables. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur.
Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Airbus vs. Boeing
(5 ans, aux fins d’illustration uniquement, données en %)

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

9.00% p.a. Early Redemption Worst of Kick-In GOAL sur Airbus / Boeing

Symbol KCZHDU
SVSP Name Barrier Reverse Convertible
SPVSP Code 1230 (Auto-Callable)
Sous-jacent Airbus / Boeing
Devise EUR
Coupon 9.00% p.a.
Kick-In Level 60%
Echéance 25.01.2021
Émetteur UBS AG, London
Date de fixation du prix 23.01.2019, 15:00 h
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 16.01.2019

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Or, Airbus & Boeing2019-02-15T12:17:12+01:00

Weekly Hits: Gold, Airbus & Boeing

KeyInvest Weekly Hits

Friday, 18.01.2019

  • Topic 1: Gold - An increase in the need for protection
  • Topic 2: Airbus/Boeing - A transatlantic duel

Gold
An increase in the need for protection

The British House of Commons has rejected the Brexit agreement negotiated with Brussels by Prime Minister Theresa May. Although the Prime Minister is now working on a “Plan B”, the risk of a “no deal” Brexit has increased. It therefore comes as no surprise that investors are increasingly turning to the crisis currency of gold (the gold price has risen by 3.7% since December 10, 2018).¹ The ETC (symbol: CGCCIU) offers transparent and efficient access to the most important precious metal. The product tracks the performance of the UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index. The main parties benefitting from the increasing gold prices are precious metal producers such as Kinross Gold, Freeport-McMoRan and Barrick Gold. This trio forms the basis for an Early Redemption (ER) Kick-In GOAL (symbol: KDAIDU). Investors can expect a coupon payment of 14% p.a. with this subscription product. In addition, the three shares prone to fluctuations have low barriers of 50% of the initial price level.

While only 202 MPs voted for the Brexit deal, a clear majority of 432 MPs rejected it. After the vote in the House of Commons, Theresa May nevertheless came out fighting and announced a plan for how to proceed next. However, we may not see this plan in action, as the leader of the opposition Jeremy Corbyn called for a vote of no-confidence (source: Thomson Reuters media report, January 16, 2019). In any case, the gold price initially showed little reaction to the crushing defeat suffered by the British government. However, the precious metal had grown considerably more expensive in the run-up to the vote, with its value increasing by 6.1% over three months.¹ In addition to the Brexit turbulence, the tariff dispute between the US and China has seen investors head to the safe haven offered by gold.

Especially as the unresolved spat is having a noticeable impact on the real economy. One such example is that in December, China reported a 7.6% decline in imports in comparison with the previous year. At the same time, exports also fell by 4.4%. Analysts had expected growth for both indicators (source: Thomson Reuters media report, January 15, 2019).
In the wake of rising precious metal prices, shares in the mining sector have provided a sign of life. In addition, a takeover has made the industry sit up and take notice, with US company Newmont Mining buying its Canadian competitor Goldcorp for USD 10 billion. If the deal actually comes to pass, this merger would see the creation of the world’s largest gold company. Back in September 2018, Barrick Gold merged with Randgold Resources, a deal that saw the company’s market value rise by USD 6.1 billion (source: Thomson Reuters media report, January 14, 2019).

Opportunities: With the ETT (symbol: CGCCIU) on the UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index, investors can add the crisis currency to their portfolios simply and cost-effectively. The underlying assets and product are denominated in Swiss francs. Any fluctuations in the exchange rate between the Swiss franc and the commodity currency, the US dollar, are hedged on a monthly basis. The Early Redemption Kick-In GOAL (symbol: KDAIDU) on Kinross Gold, Freeport-McMoRan and Barrick Gold provides investors with a partially protected position in the mining sector. Provided that none of the underlyings touch or fall below the barrier of 50%, the product will pay a return of 14% p.a. on the maturity date. Investors may also be able to get their hands on this return at a much earlier date. Thanks to the Early Redemption function, the term can be shortened.

Risks: The aforementioned products do not have capital protection. The ETC will make a loss if the underlying index decreases. If the underlying assets for the ER Kick-In GOAL equal or fall below the respective kick-in level (barrier) and the early redemption feature does not apply, the amount repaid on maturity may be in cash, reflecting the worst performance of the underlyings (but not more than nominal value plus coupon). In this case, it is likely that losses will be incurred. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Gold (in US dollars per fine ounce) 5 years¹

Gold has been trending upwards strongly for around three years. While experiencing huge fluctuations, the troy ounce rose in price from less than USD 1,100 to just under USD 1,300.

Source: UBS AG, Bloomberg

As of 16.01.2019

Kinross Gold vs. Freeport-McMoRan vs. Barrick Gold
(five years, for illustrative purposes only, figures in %)¹

The gold sector has had quite a hard time with investors in recent years. All the same, the prices of shares in Kinross Gold,
Freeport-McMoRan and Barrick Gold have stabilized somewhat.

Source: UBS AG, Bloomberg

As of: 16.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

ETC on UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index

Symbol CGCCIU
SVSP Name Tracker Certificates
SPVSP Code 1300
Underlying UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index
Currency CHF
Ratio 10:1
Administration fee 0.38% p.a.
Expiry Open End
Participation 100%
Issuer UBS AG, London
Bid/Ask CHF 77.70 / 78.05
 
Termsheet

14.00% p.a. Early Redemption Worst of Kick-In GOAL on Kinross Gold / FreeportMcRoran / Goldstone

Symbol KDAIDU
SVSP Name Barrier Reverse Convertibles
SPVSP Code 1230 (Auto-Callable)
Underlying Kinross Gold / Freeport-McMoRan / Barrick Gold
Currency USD
Coupon 14.00% p.a.
Kick-In Level
 50%
Expiry 30.01.2020
Issuer UBS AG, London
Subscription until 30.01.2019, 15:00 h
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 16.01.2019

Market overview

Index Quotation Week¹
SMI™ 8’873.77 2.1%
SLI™ 1’374.48 2.4%
S&P 500™ 2’616.10 1.2%
Euro STOXX 50™ 3’077.22 0.2%
S&P™ BRIC 40 4’012.62 1.0%
CMCI™ Compos. 893.02 -0.2%
Gold (troy ounce) 1’293.80 USD 0.1%

¹ Change based on the closing price of the previous day compared to the closing price a week ago.

SMI™ vs. VSMI™ 1 year

smi vs vsmi

The VSMI™ Index is calculated since 2005. It shows the volatility of the stocks within the SMI™ index. A portfolio which reacts only to changes in volatility instead of volatility itself is relevant for the calculation. Thereby, the VSMI™ methodology uses the squared volatility, known as variance, of the SMI options with remaining time to expiry of 30 days traded at the Eurex.

Source: UBS AG, Bloomberg

As of: 16.01.2019

Airbus/Boeing
A transatlantic duel

The year had barely come to a close when the two largest aircraft manufacturers in the world presented their operating balance sheets. In 2018, Boeing supplied a total of 806 aircraft and in doing slightly outperformed Airbus, with its rival delivering 800 aircraft to airline and leasing companies. Boeing also led the race on the stock exchange in 2018. As a result, the Dow Jones™ stock thus extended its longer-term lead over Airbus (see chart).¹ With a new Early Redemption (ER) Kick-In GOAL (symbol: KCZHDU), investors are counting on the two large caps to be able to maintain their current altitude on the market and avoid too much turbulence during the term. The annual coupon of 9% comes with a safety buffer of 40%.

Following a strong end to the year, Airbus has succeeded in meeting its own delivery target for 2018 with pinpoint accuracy. Due to problems with the supply of engines, there had been doubts that this forecast would be met in recent months. Despite all the cries of the naysayers, the European group has increased deliveries for the 16th year in a row. Airbus also posted another record year in 2018 with year-on-year growth of 11%. During this time, however, there was a decline in new orders. The company recorded 747 net orders, compared with 1,109 in the previous year. Nevertheless, a record-high order backlog of 7,577 commercial aircraft had piled up at the end of 2018 (source: Airbus media release, January 9, 2019).

By delivering 806 jet aircraft, Boeing also set a new record in 2018, which saw the Seattle-based group enjoying year-on-year growth of 5.6%. At the same time, the company received orders for a net total of 893 aircraft with a total value of USD 143.7 billion. The 737 MAX remains Boeing’s best-selling product, with 675 net orders being placed for this model in 2018. In December, the program hit the 5,000 net orders mark (source: Boeing media release, January 8, 2019).

Opportunities: UBS has combined the shares in the aircraft manufacturers, both of which have been rated as «Buy” by UBS’ inhouse research department, as the underlying assets for an ER Kick-In GOAL (symbol: KCZHDU). A coupon of 9% p.a. is available on the two shares. This return opportunity comes with a barrier of a low 60% of the starting price. The Early Redemption function makes it possible for the maximum return to be paid out early. This requires that both shares close at or above their respective initial prices on one of the observation days.

Risks: This product does not have capital protection. If the underlyings equal or fall below the respective kick-in level (barrier) and the early redemption feature does not apply, the amount repaid on the date of maturity may be in cash, reflecting the worst performance of the two shares (but not more than nominal value plus coupon). In this case, it is likely that losses will be incurred. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Airbus vs. Boeing
(five years, for illustrative purposes only, figures in %)¹

Source: UBS AG, Bloomberg

As of: 16.01.2019

9.00% p.a. Early Redemption Worst of Kick-In GOAL on Airbus / Boeing

Symbol KCZHDU
SVSP Name Barrier Reverse Convertibles
SPVSP Code 1230 (Auto-Callable)
Underlyings Airbus / Boeing
Currency EUR
Coupon 9.00% p.a.
Kick-In Level 60%
Expiry 25.01.2021
Issuer UBS AG, London
Subscription until 23.01.2019, 15:00 h
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 16.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Gold, Airbus & Boeing2019-02-15T12:08:47+01:00

Ein Auftakt nach Mass

KeyInvest Blog

14. Januar 2019 – UBS Wochenkommentar Rück-/Ausblick

Ein Auftakt nach Mass

Mit viel Selbstvertrauen sind Anleger in das neue Jahr gestartet. Der SMI legte in den ersten Handelstagen mehr als vier Prozent zu und lugte sogar wieder über die 8’800er-Marke. Mit dem dynamischen Anstieg verwies der heimische Leitindex seine europäischen «Kontrahenten» wie den DAX oder EURO STOXX 50 klar in die Schranken. Die Bullen haben das Ruder also wieder übernommen, fragt sich nur für wie lange?

Deeskalation auf der einen Seite…

Unterstützt wird die aktuelle Aufwärtsbewegung von einer Entschärfung im Zollstreit zwischen den USA und China. Hoffnungen schöpfen die Märkte auf den dreitägigen Verhandlungen in Peking zwischen den beiden Grossmächten. Laut dem chinesischen Handelsministerium haben die Gespräche «das gegenseitige Verständnis vergrössert und eine Grundlage geschaffen, um die Besorgnisse beider Seiten anzusprechen». (Quelle: dpa, 10.01.2019) Von einer tatsächlichen Einigung sind die Staaten aber noch weit entfernt. Die nächste Chance, einen weiteren Schritt aufeinander zuzugehen, haben die Protagonisten auf dem Weltwirtschaftsforum in Davos, das vom 22. bis 25. Januar stattfinden wird. Allerdings hat US-Präsident Trump aufgrund des anhaltenden Regierungsstillstands in den USA seine persönliche Teilnahme abgesagt.

…Zuspitzung auf der anderen

Während sich im Reich der Mitte möglicherweise die Wogen etwas glätten, ist der Konfrontationskurs zwischen Grossbritannien und der EU in vollem Gange. Lange wurde im britischen Unterhaus über den Brexit-Vertrag, den Premierministerin Theresa May mit der EU ausgehandelt hat, debattiert. Am Dienstag soll nun die Abstimmung erfolgen. Eine Zustimmung ist für einen geregelten Brexit entscheidend, denn bereits am 29. März möchte das Land die EU verlassen. Allerdings bläst May starker Wind entgegen. Zum Beispiel steht die nordirische DUP den Plänen der Regierung kritisch gegenüber. Ihrer Ansicht nach sei der Brexit-Vertrag insgesamt ruinös und so nicht zustimmungsfähig. (Quelle: Thomson Reuters, 09.01.2019) Der ungewisse Ausgang der Abstimmung und der Zeit danach, möglicherweise kommt es doch noch zu Neuwahlen respektive einer zweiten Brexit-Volksabstimmung, könnte die Börsen in der neuen Woche wieder einholen.

Auf dem Währungsmarkt ist von der Euphorie der Aktienhändler zu Jahresbeginn nicht viel zu erkennen. Der Schweizer Franken scheint als «Sicherer Hafen» weiterhin gefragt zu sein. Das Währungspaar pendelte in den ersten Handelstagen 2019 im Wesentlichen um die Marke von 1.1250 Franken gegenüber dem Euro. Und das, obwohl SNB-Direktoriumsmitglied Fritz Zurbrügg in einem jüngsten Interview mit dem Schweizer Radio und Fernsehen (SRF) klar stellte, dass es keinen Grund gibt, die expansive Geldpolitik zu ändern: «Wir brauchen immer noch die Negativzinsen und die Bereitschaft, an den Devisenmärkten zu intervenieren.» Für Zurbrügg ist der Franken immer noch hoch bewertet. (Quelle: FuW, 08.01.2019)

Ob die SNB auf dem aktuellen Niveau interveniert, lässt sich nicht sagen. Aber das Devisenpaar scheint im Bereich von 1,12 Euro eine Unterstützung gefunden zu haben. Im Herbst vergangenen Jahres zeigte sich auf diesem Niveau ein ähnliches Kursmuster.  Für den Fall, dass es in Grossbritannien nicht zu einem Chaos beim EU-Austritt kommt, könnte der Euro wieder Oberhand gewinnen. Wer auf ein positives Szenario bei EUR/CHF setzen möchte, kann einen Blick auf das Hebelprodukt-Angebot der UBS werfen. Beispielsweise würde der Open End Turbo Call Warrant (Symbol: OCHFXU) von einer Aufwertung des Euro gegenüber dem Franken überproportional profitieren. Selbstverständlich befinden sich auch Short-Produkte in der Palette, um die Gegenseite zu spielen.

Was uns diese Woche erwartet

Neben der bereits erwähnten wichtigen Abstimmung der Briten stehen diese Woche noch jede Menge makroökonomischer Daten auf dem Kalender. Am Dienstag wird es bei unseren deutschen Nachbarn interessant. In Berlin wird das BIP-Wachstum für 2018 bekanntgegeben. Dies ist vor allem aufgrund der drohenden technischen Rezession interessant. Im dritten Quartal verzeichnete das Land nämlich bereits ein Minuswachstum. Einen Tag später werden Zahlen zur Verfassung der chinesischen Wirtschaft – Einzelhandelsumsätze sowie die Industrieproduktion – erwartet. Am selben Tag wird auch die USA ihre Einzelhandelsumsätze veröffentlichen. In Europa warten Investoren dagegen auf die Verbraucherpreisindizes in Deutschland und Grossbritannien. Am Montag, 21. Januar, kommt es dann zu einer Art Showdown für die Weltkonjunktur. Dann wird Peking die mit grosser Spannnung erwarteten Zahlen zum Bruttoinlandsprodukt für das Schlussviertel im vergangenen Jahr vorlegen. Im Vorfeld wurden bereits vorsichtige Stimmen laut. Es sei durchaus möglich, dass das Wachstum im vierten Quartal 2018 unter die Schwelle von 6,5 Prozent gefallen sei, heisst es in einer am 2. Januar 2019 Publikation der chinesischen Notenbank. Medienberichten zufolge rechnet die Führung in Peking für 2019 ebenfalls nur noch mit einem Plus von sechs bis 6,5 Prozent. Das offizielle Wachstumsziel soll bei der jährlichen Parlamentssitzung im März bekanntgegeben werden. (Quelle: Thomson Reuters, 11.01.2019)

Wichtige Termine

Stand: 11.01.2019; Quelle: Bloomberg, Thomson Reuters

Weitere Blogeinträge:

Fussball, Glühwein und Feiertage

Die Vorweihnachtszeit hält langsam aber sicher Einzug. In mehreren Schweizer Städten, darunter St. Gallen, Basel und Zürich, beginnen am 24. November die Weihnachtsmärkte. Diese beliebten Anlässe bieten eine gute Gelegenheit, um das Jahr Revue passieren zu lassen.

Unterschiedliche Taktgeber

In der vergangenen Woche blieb kein Börsenauge trocken. In der ersten Hälfte dominierten noch die Bären das Geschehen. Auf der einen Seite trieben drohende neue Lockdowns in China den Investoren Sorgenfalten auf die Stirn.

Ein Wechselbad der Gefühle

Gerade einmal 23 Zeilen umfasst das von der US-Notenbank am 2. November 2022 veröffentlichte geldpolitische Statement. Dieser kurze Text reichte, um die Börsen – quer durch die Anlageklassen – in Aufruhr zu versetzen. Während die Aktienkurse an der Wall Street nach unten drehten, wertete der US-Dollar deutlich auf.

Ein Auftakt nach Mass2019-01-14T10:01:13+01:00

Weekly Hits: L’industrie automobile & Le secteur biotechnologique

KeyInvest Weekly Hits

Vendredi, 11.01.2019

  • Thème 1: L’industrie automobile - Une finition brillante
  • Thème 2: Le secteur biotechnologique - La vague de reprises se poursuit

L’industrie automobile
Une finition brillante

De vraies montagnes russes: depuis des mois, l’industrie automobile subit la douche écossaise des sentiments. Si le secteur brille par des perspectives autonomes, la mise en réseau numérique et des stimuli novateurs, des craintes conjoncturelles et des conflits commerciaux génèrent quant à eux de fortes inquiétudes. Ces dernières ont dominé l’année dernière, faisant chuter les cours au plus bas.¹ Il n’est pas encore certain que le secteur arrivera à changer d’orientation en 2019. Toutefois, lors du prochain salon Detroit Motor Show, les groupes présenteront leurs atouts pour l’avenir. L’ETT sur le STOXX™ Europe 600 Automobiles & Parts NR Index (symbole : ETAUT) offre aux investisseurs l’opportunité de s’engager dans le secteur de manière diversifiée et sans frais.² Le IC Kick-In GOAL (symbole : KCZTDU) sur BMW, Daimler et VW présente une alternative. Le produit dispose d’une marge de 40% et d’un coupon de 10.00% p.a.

Pour faire impression, les constructeurs ont brillamment assuré les finitions de leurs carrosses, et ils présentent leurs modèles étendards sur divers salons. Traditionnellement, le North American International Auto Show (NAIAS) lance l’année, et ce depuis 1907 déjà. Mais cette fois, il s’agira de la dernière édition à Detroit. Dès 2020, le NAIAS deviendra un événement d’été qui se tiendra en juillet. Toutefois, cette année, le salon ouvrira ses portes le 14 janvier, et présentera de nombreuses nouveautés. Les organisateurs prévoient la présentation de plus de 30 premières. Avec en tête les groupes automobiles américains. Ford engagera notamment dans la course le Shelby GT500 (avec environ 700 ch), et Fiat-Chrysler proposera un nouveau pick-up Ram Heavy Duty avec des phares LED. Les marques américaines ne seront pas les seuls à chercher à attirer l’attention du public local. Les constructeurs européens démontreront aussi leurs compétences à Detroit. Par exemple Volkswagen, qui dévoilera la US-Passat en format Limousin.

Si VW se rend dans les frimas de Detroit, ses concurrents BMW et Daimler préfèrent le CES à Las Vegas. Le Consumer Electronics Show n’est pas à proprement parler un salon automobile. Toutefois, les constructeurs sont toujours plus nombreux à se rendre dans cette ville au cœur du désert. Du 8 au 12 janvier, les fabricants présentent ici surtout leurs concepts technologiques. BMW y exposera un véhicule autonome et Mercedes-Benz y présentera le CLA, une première mondiale. Ce modèle dispose de plusieurs systèmes d’assistance très pratiques.
S’agissant de la vente de véhicules américains, Daimler a eu une longueur d’avance. En 2018, avec 315 959 unités vendues, la marque a été à nouveau numéro un des véhicules de luxe les plus vendus aux Etats-Unis. BMW occupe la seconde place, tout juste derrière. Et les Bavarois rattrapent leur retard: Alors que finalement, Daimler a vendu 6.3% de véhicules en moins, la marque au logo blanc et bleu a enregistré une hausse de 1.7%. (Source : Manager Magazin, article de presse, 04.01.2019)

Opportunités: le monde de l’automobile est à l’aube d’un changement fondamental. Et cela implique des risques (investissements se chiffrant en milliards), mais également des opportunités (innovations produits). Les investisseurs qui croient à une réorientation en 2019 (le STOXX™ Europe 600 Automobiles & Parts Index a perdu 28% l’année dernière) peuvent miser sur une stratégie à long terme avec l’ETT (symbole : ETAUT).¹ Le produit offre une pleine participation, les distributions nettes des 16 membres étant prises en considération. Et il s’agit là d’un facteur important, car le rendement en dividendes de l’indice s’établit à 2,5%. Aucune commission annuelle n’est facturée.² Il est possible d’investir également avec un « airbag » dans les poids lourds de l’indice BMW, Daimler et VW avec le nouveau IC Kick- In GOAL (symbole : KCZTDU). La marge de sécurité s’établit à un confortable 40%, le coupon affiche un sympathique 10.00% p.a.

Risques: les produits présentés n’offrent pas de protection du capital. Une évolution négative de l’actif sous-jacent entraîne des pertes correspondantes pour l’ETT. Si, pendant la durée de l’investissement, un des sous-jacents du Worst of Kick-In GOAL atteint une seule fois sa barrière respective (« Kick-In Level ») ou est inférieur à celle-ci, et que par ailleurs la fonction Issuer-Callable ne s’applique pas, le montant remboursé en espèces à maturité par amortissement est basé sur la performance la plus faible (base Strike) du trio (au maximum toutefois à la valeur nominale majorée du coupon). Dans un tel cas, des pertes sont probables. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur. Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

STOXX™ Europe 600 Automobiles & Parts NR Index vs. STOXX™ Europe 600 NR Index
(5 ans, aux fins d’illustration uniquement, données en%)¹

«Hors des frais, pas grand-chose», cette phrase s’applique à l’évolution sur cinq ans du STOXX™ Europe 600 Automobiles & Parts Index. L’indice STOXX™ Europe 600 a quant à lui progressé de 20%.

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

BMW vs. Daimler vs. Volkswagen VZ
(5 ans, aux fins d’illustration uniquement, données en%)¹

On remarque de nettes traces de ralentissement pour les actions de BMW, Daimler et Volkswagen sur cinq ans. Ces deux dernières années, le trio automobile allemand est passé à la conduite latérale.

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

ETT sur STOXX™ Europe 600 Automobiles & Parts NR Index

Symbol ETAUT
SVSP Name Tracker Certifikat
SPVSP Code 1300
Sous-jacent STOXX™ Europe 600 Automobiles & Parts EUR Net Return Index
Devise EUR
Rapport de souscription 1:1
Frais de gestion 0.00% p.a.²
Participation 100%
Echéance Open End
Émetteur UBS AG, London
Bid/Ask EUR 812.00 / 816.50
 
Termsheet

10.00% p.a. IC Worst of Kick-In GOAL sur BMW / Daimler / Volkswagen

Symbol KCZTDU
SVSP Name Barrier Reverse Convertible
SPVSP Code 1230 (Callable)
Sous-jacent BMW / Daimler / Volkswagen
Devise EUR
Coupon 10.00% p.a.
Kick-In Level 60%
Echéance 23.07.2020
Émetteur UBS AG, London
Date de fixation du prix 23.01.2019, 15:00 h
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

Apérçu du marché

Index Citation Semaine¹
SMI™ 8’687.71 3.1%
SLI™ 1’342.15 3.6%
S&P 500™ 2’584.96 3.0%
Euro STOXX 50™ 3’070.24 2.6%
S&P™ BRIC 40 3’970.99 5.8%
CMCI™ Compos. 894.73 5.0%
Gold (troy ounce) 1292.00 USD 0.6%

¹ Changement basé sur le cours de clôture du jour précédent par rapport au cours de clôture de la semaine dernière.

SMI™ vs. VSMI™ 1 année

L’index VSMI™ est calculé depuis 2005. Il affiche la volatilité des actions inclus dans le SMI™ index. Pour la calculation, un portefeuille est utilisé qui ne réagit qu’au variations de la volatilité au lieu des variations des prix. En le faisant, la méthodologie du VSMI™ utilise la volatilité carré, connu sous le terme variance, des options sur le SMI avec 30 jours jusqu’à l’échéance négociées à la Bourse Eurex.

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

Le secteur biotechnologique
La vague de reprises se poursuit

A Wall Street, l’année a débuté avec un coup de timbale: Le 3 janvier, le géant pharmaceutique Bristol-Myers Squib a présenté une offre de reprise de 74 milliards de dollars au groupe de biotechnologie Celgene. Quelques jours plus tard à peine, Elli Lilly a renforcé la vague de concentration dans le secteur. Cette entreprise brigue Loxo Oncology avec une offre en espèces de huit milliards de dollars. A la suite de ces deux accords, le Kick-In GOAL (symbole : KCFZDU) sur Celgene, Amgen et Johnson a connu également un début d’année bien rythmé.¹ En dépit des avancées, le produit permet d’envisager un rendement latéral de 10.4% p.a. Cette opportunité de rendement attrayante va de pair avec un écart de la barrière de 37.5%, même pour le Worst Performer du moment (Celgene).

Avec Celgene, Bristol-Myers Squib souhaite lancer très bientôt une série de médicaments phares sur le marché. Concrètement, six nouveaux produits avec un potentiel de chiffre d’affaires supérieur à 15 milliards de dollars devraient être lancés prochainement. Dans ce contexte, la priorité va à la fusion prévue pour l’immunothérapie. L’année dernière seulement, Celgene a renforcé ce domaine de traitement avec l’achat pour neuf milliards de dollars US de Juno Therapeutics. (Source : Thomson Reuters, article de presse, 03.01.2019).

Depuis toujours, l’oncologie a été importante, également pour l’activité d’Amgen. Ce n’est qu’en décembre que le géant de la biotechnologie a annoncé sa collaboration stratégique avec l’entreprise suisse Molecular Partners, dans le domaine de l’immunothérapie. Cette alliance transatlantique porte sur le développement clinique et la commercialisation du « MP0310 ». Cette substance active est censée activer les cellules immunitaires d’une tumeur. (Source : Thomson Reuters, article de presse, 19.12.2018). L’oncologie s’est récemment développée comme un moteur de croissance pour le groupe Johnson & Johnson actif dans le secteur de la santé. C’est le cas notamment de Zytiga, une substance active destinée au traitement du cancer de la prostate. Avec d’autres produits, elle a apporté à la division pharmaceutique une hausse de 8.2% du chiffre d’affaires opérationnel au troisième trimestre. (Source : Johnson & Johnson, communiqué de presse, 16 octobre 2018)

Opportunités: une évolution de cours relativement stable de Amgen, Celgene et Johnson & Johnson sur les sept prochains mois suffira pour permettre un rendement latéral de 10.4% p.a. avec le Kick-In GOAL (symbole : KCFZDU). Il est déterminant qu’aucun des trois sous-jacents n’atteigne ou ne soit inférieur à la barrière jusqu’à l’échéance en août. Par rapport au cours d’émission, actuellement, Celgene affiche l’évolution la plus faible. Quoi qu’il en soit, le membre du Nasdaq-100™ dispose encore d’une marge de sécurité de 37.5%.

Risques: les Kick-In GOALS ne bénéficient d’aucune protection du capital. Si, pendant la durée de l’investissement, l’un des sous-jacents atteint une seule fois la barrière respective (« Kick-In Level ») ou est inférieur à celle-ci, le remboursement par amortissement en espèces à l’échéance est basé sur la performance la plus faible (base Strike) du trio (au maximum toutefois à la valeur nominale majorée du coupon). Dans un tel cas, des pertes sont probables. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur. Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Amgen vs. Celgene vs. Johnson & Johnson
(5 ans, aux fins d’illustration uniquement, données en %)

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

6.50% p.a. Kick-In GOAL sur Amgen / Celgene / Johnson & Johnson

Symbol KCFZDU
SVSP Name Barrier Reverse Convertible
SPVSP Code 1230
Sous-jacent Amgen / Celgene Corporation / Johnson & Johnson
Devise USD
Coupon 6.50% p.a.
Rendement latéraux 6.48% (10.38% p.a.)
Kick-In Level (Distance) Amgen: USD 118.704
(41.10%)
Celgene: USD 54.384
(37.45%)
Johnson & Johnson: USD 80.766
(37.50%)
Echéance 22.08.2019
Émetteur UBS AG, London
Bid/Ask 96.61% / 97.64%
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 10.01.2019

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: L’industrie automobile & Le secteur biotechnologique2019-02-15T12:17:48+01:00

Weekly Hits: Automotive industry & Biotech sector

KeyInvest Weekly Hits

Friday, 11.01.2019

  • Topic 1: Automotive industry - Given a polish
  • Topic 2: Biotech sector - Wave of acquisitions set to continue

Automotive industry
Given a polish

With jubilant highs and sorry lows, the automotive industry has endured a rollercoaster of emotions in recent months. Although the prospects of autonomous technology, digital networking and innovative engines have been a ray of light for the industry, economic uncertainty and trade conflicts are providing a much gloomier picture. There has been a prevailing sense of concern over the past year and prices have hit rock bottom¹. It is, however, still unclear whether the sector will experience a change in direction in 2019. At the upcoming Detroit Motor Show, automotive groups will be revealing what they have to offer under the hoods of their vehicles. The ETT on the STOXX™ Europe 600 Automobiles & Parts NR Index (symbol: ETAUT) provides investors with the opportunity to participate in the sector in a diversified manner and without having to pay any fees.² A viable alternative is also presented in the form of the new IC Kick-In GOAL (symbol: KCZTDU) on BMW, Daimler and VW. The product has a buffer of 40% as well as an annual coupon of 10%.

In order to make an impression with those in attendance, the manufacturers polished their cars at the beginning of the year and will present the highlights of their product ranges at various trade fairs. Traditionally, the North American International Auto Show (NAIAS) announces the start of the year for the automotive industry – and has done so since 1907. However, this is the last time the Detroit show will take place in January. From 2020 onwards, the NAIAS will be a summer event held in July. The trade fair opens its gates on January 14 this year, with numerous innovations at which guests can marvel. The organizers expect more than 30 new models to make their debut, with the American automotive groups taking center stage. Ford will enter the race with, among other vehicles, the 700-horsepower Shelby GT500 and Fiat-Chrysler will showcase a new Ram Heavy Duty pickup with LED lights. But it’s not just the US brands that want to impress the domestic audience; European manufacturers will also be showing what they have to offer in Detroit. For example, Volkswagen will unveil the US Passat as its latest sedan model.

While VW will be travelling to cold Detroit, its competitors BMW and Daimler prefer to make an appearance at the CES in Las Vegas. Although the Consumer Electronics Show is not really a motor show, an increasing number of car makers are making the journey to the desert city. From January 8–12, the manufacturers will be primarily presenting their technological concepts at the show. While BMW will be showcasing a self-driving motorcycle, Mercedes-Benz will be giving the CLA its world premiere. The model comes equipped with a number of assistance systems, such as gesture controls.
As far as US vehicle sales are concerned, Daimler has recently been in pole position. With 315,959 vehicles sold in 2018, the brand once again took first place among the most sold luxury vehicles in the USA. BMW is not far behind in second place and is catching up: While Daimler experienced a 6.3% decline in the number of cars sold, the Bavarian company recorded an increase of 1.7% (source: Manager Magazin media report, January 4, 2019).

Opportunities: The car world is facing upheaval. This presents risks (billion-dollar investments) as well as opportunities (product innovations). Should you feel that there will be a change in direction in 2019 – the STOXX™ Europe 600 Automobiles & Parts Index fell by 28% last year– you can implement a long strategy with the ETT (symbol: ETAUT).¹ The product offers full participation, taking into account the net distributions of the 16 members. This is a factor not to be underestimated, as the dividend yield of the index stands at 2.5%. There is no annual fee.² With the new IC Kick- In GOAL (symbol: KCZTDU), investments can be made in the index heavyweights BMW, Daimler and VW with an “airbag”. The product has a comfortable risk buffer of 40% and an attractive annual coupon of 10%.

Risks: The aforementioned products do not have capital protection. Should the underlying assets deliver a negative performance, the ETT will incur commensurate losses. If the underlying assets for the Worst of Kick-In GOALS equal or fall below the respective kick-in level (barrier) and the issuer callable feature does not apply, the amount repaid on maturity may be in cash, reflecting the worst performance of the three shares (but not more than nominal value plus coupon). In this case, it is likely that losses will be incurred. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

STOXX™ Europe 600 Automobiles & Parts NR Index vs. STOXX™ Europe 600 NR Index
(five years, for illustrative purposes only, figures in %)¹

“Nothing gained, nothing lost” – this figure of speech holds true for the five-year trend of the STOXX™ Europe 600 Automobiles & Parts Index. Meanwhile, the broad STOXX™ Europe 600 Index rose by 20%.

Source: UBS AG, Bloomberg

As of 10.01.2019

BMW vs. Daimler vs. Volkswagen VZ
(five years, for illustrative purposes only, figures in %)¹

The shares of BMW, Daimler and Volkswagen are showing clear signs of slowing down in the five-year chart. Over the past two years, the shares in the three German automotive companies have at least moved sideways.

Source: UBS AG, Bloomberg

As of: 10.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

ETT on STOXX™ Europe 600 Automobiles & Parts NR Index

Symbol ETAUT
SVSP Name Tracker Certificates
SPVSP Code 1300
Underlying STOXX™ Europe 600 Automobiles & Parts EUR Net Return Index
Currency EUR
Ratio 1:1
Administration fee 0.00% p.a.²
Expiry Open End
Participation 100%
Issuer UBS AG, London
Bid/Ask EUR 812.00 / 816.50
 
Termsheet

10.00% p.a. IC Worst of Kick-In GOAL on BMW / Daimler / Volkswagen

Symbol KCZTDU
SVSP Name Barrier Reverse Convertibl
SPVSP Code 1230 (Callable)
Underlying BMW / Daimler / Volkswagen
Currency EUR
Coupon 10.00% p.a.
Kick-In Level
 60%
Expiry 23.07.2020
Issuer UBS AG, London
Subscription until 23.01.2019, 15:00 h
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 10.01.2019

Market overview

Index Quotation Week¹
SMI™ 8’687.71 3.1%
SLI™ 1’342.15 3.6%
S&P 500™ 2’584.96 3.0%
Euro STOXX 50™ 3’070.24 2.6%
S&P™ BRIC 40 3’970.99 5.8%
CMCI™ Compos. 894.73 5.0%
Gold (troy ounce) 1292.00 USD 0.6%

¹ Change based on the closing price of the previous day compared to the closing price a week ago.

SMI™ vs. VSMI™ 1 year

smi vs vsmi

The VSMI™ Index is calculated since 2005. It shows the volatility of the stocks within the SMI™ index. A portfolio which reacts only to changes in volatility instead of volatility itself is relevant for the calculation. Thereby, the VSMI™ methodology uses the squared volatility, known as variance, of the SMI options with remaining time to expiry of 30 days traded at the Eurex.

Source: UBS AG, Bloomberg

As of: 10.01.2019

Biotech sector
Wave of acquisitions set to continue

The new year began with a bang on Wall Street, as pharmaceutical giant Bristol-Myers Squib submitted a USD 74 billion takeover bid for the Celgene biotech group on January 3. And just a few days later, Eli Lilly added to the wave of takeovers in the sector. The American company is courting Loxo Oncology with an USD 8 billion cash offer. In the wake of both deals, the kick-in GOAL (symbol: KCFZDU) on Celgene, Amgen and Johnson & Johnson also experienced a lively start to the year.¹ Notwithstanding the gains, the product offers the prospect of a minimum return of 10.4% p.a. Even with the current worst performer (Celgene), this attractive opportunity comes with a barrier of 37.5%.

Together with Celgene, Bristol-Myers Squib will soon be launching a series of blockbusters on the market. Specifically, six new drugs with a sales potential of more than USD 15 billion are to be launched in the near future. One of the key aspects in the planned merger is cancer immunotherapy. Celgene boosted its expertise in this field of treatment last year with the USD 9 billion acquisition of Juno Therapeutics (source: Thomson Reuters media report, January 3, 2019).

Oncology has always played an important role in Amgen’s business. As recently as in December of last year, the biotech giant announced its strategic collaboration in the field of immunotherapy with Swiss company Molecular Partners. The transatlantic alliance will focus on the clinical development and commercialization of “MP0310”. The aim of this active ingredient is to activate the immune cells in a tumor (source: Thomson Reuters media report, December 19, 2018). Oncology has recently emerged as a growth driver for the Johnson & Johnson healthcare company. One example of this is Zytiga, an active ingredient used to treat prostate cancer. Together with other products, it generated an operating sales growth of 8.2% for the company’s Pharmaceuticals division in the third quarter of 2018 (source: Johnson & Johnson media release, October 16, 2018).

Opportunities: Should the share prices of Amgen, Celgene and Johnson
& Johnson remain more or less stable over the next seven months, a minimum annual yield of 10.4% can be achieved with the Kick-In GOAL (symbol: KCFZDU). This will require that none of the three underlyings touch or fall below the barrier before the maturity date in August. In contrast to when the shares were issued, Celgene currently has the weakest price performance. Nevertheless, the Nasdaq 100™ member still has a safety buffer of 37.5%.

Risks: Kick-In GOALs do not have capital protection. If one of the underlyings equals or falls below the respective kick-in level (barrier) during the term, the amount repaid on the date of maturity may be in cash, reflecting the worst performance of the three shares from the strike price (but not more than nominal value plus coupon). In this case, it is likely that losses will be incurred. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Amgen vs. Celgene vs. Johnson & Johnson
(five years, for illustrative purposes only, figures in %)¹

Source: UBS AG, Bloomberg

As of: 10.01.2019

6.50% p.a. Kick-In GOAL on Amgen / Celgene / Johnson & Johnson

Symbol KCFZDU
SVSP Name Barrier Reverse Convertible
SPVSP Code 1230
Underlyings Amgen / Celgene Corporation / Johnson & Johnson
Currency USD
Coupon 6.50% p.a.
Sideways return 6.48% (10.38% p.a.)
Kick-In Level (Distance) Amgen: USD 118.704
(41.10%)
Celgene: USD 54.384
(37.45%)
Johnson & Johnson: USD 80.766
(37.50%)
Expiry 22.08.2019
Issuer UBS AG, London
Bid/Ask 96.61% / 97.64%
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 10.01.2019

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Automotive industry & Biotech sector2019-02-15T12:11:47+01:00

USA: Neues Jahr, neues Glück

KeyInvest Blog

7. Januar 2019 – UBS Wochenkommentar Rück-/Ausblick

USA: Neues Jahr, neues Glück

Die seit 2009 andauernde Bullen-Party in den USA fand 2018 ein Ende. Rund sechs Prozent tauchten der Dow Jones und S&P 500 ab. Damit geht das Jahr als das schwächste seit einer Dekade in die Analen ein. Besonders im Dezember rauschten die Kurse in die Tiefe: Gemessen an Punkten verzeichneten der Dow Jones (-2’211 Punkte) und der S&P 500 (-254 Punkte) zuletzt im Jahr 1931 einen derartig ausgeprägten Rücksetzer.

Bullen vs. Bären

«Schlägt die Hausse nun in eine Baisse um?», lautet die Frage, die sich Börsianer nun rund um den Globus stellen. US-Präsident Donald Trump liefert gleich zu Jahresbeginn die Antwort: Er stuft die jüngsten Kursverluste am US-Aktienmarkt lediglich als «Panne» ein und geht davon aus, dass es nach den Unterzeichnungen der verschiedenen Handels-Verträge der USA mit anderen Ländern an den Märkten wieder bergauf gehen wird.

Anleger sollten dieses politische Gepolter allerdings nicht zu Ernst nehmen, sondern sich lieber selbst einen Eindruck über die aktuelle fundamentale Lage machen. Auf der einen Seite zeigt sich die Wirtschaft noch überaus robust. So wird das Wachstum seitens des privaten Verbrauchs von der guten Lage am Arbeitsmarkt weiterhin unterstützt. Auf der anderen Seite trüben sich die Aussichten in der US-Industrie ein. Der Einkaufsmanager-Index fiel im Dezember auf 54,1 Punkte von 59,3 im Vormonat. Einen derartig starken Einbruch verzeichnete das Barometer seit Oktober 2008 nicht mehr. Nach Schätzungen des IWF wird der Aufschwung 2019 etwas an Dynamik verlieren. Nach geschätzten 2,9 Prozent in 2018 prognostizieren die Experten für das neue Jahr nur noch ein Plus von 2,5 Prozent. (Quelle: imf.org)

Die Gewinndynamik ebbt ab

Im Zuge dessen werden sich auch die Unternehmensgewinne abschwächen, was allerdings nach einem erwarteten Anstieg von 20,3 Prozent in 2018 nicht unbedingt verwundern sollte. Derzeit geht der Konsens für den S&P 500 mit einem Ergebniswachstum von 7,9 Prozent sowie einem Umsatzanstieg von 5,3 Prozent aus. Den Schätzungen zufolge soll der Industriesektor mit einem Zuwachs von 11,4 Prozent am besten abschneiden. Lediglich ein unterdurchschnittliches Plus von sieben Prozent erwartet die Analystenzunft im Technologiesektor. (Quelle: Facset, Earnings Insight, 28.12.2018)

Dass die Vorsicht gegenüber den langjährigen Zugpferden berechtigt sein könnte, zeigte die Umsatzwarnung von Apple am ersten Börsentag des neuen Jahres. Insbesondere aufgrund eines schwachen Geschäfts in China kürzte der Kultkonzern seine Erwartungen für das erste Quartal. Wurden bisher Erlöse zwischen 89 bis 93 Milliarden erwartet, lautet die Prognose nun nur noch auf 84 Milliarden US-Dollar.

Wenn auch die S&P 500-Unternehmen 2019 etwas kleinere Brötchen backen müssen, die Profitabilität soll darunter nicht leiden. Im Gegenteil: Der Konsens rechnet bei der Nettomarge mit einem neuen Rekordwert von durchschnittlich 11,8 Prozent. Das wäre eine Steigerung im Vergleich zum erwarteten Vorjahreswert um 0,3 Prozentpunkte. (Quelle: Facset, Earnings Insight, 28.12.2018)

Das Fed wird vorsichtiger

Grösseren Marktkorrekturen gehen gewöhnlich makroökonomische Schocks, starke Gewinn-Revisionen oder auch unerwartet hohe Sprünge bei den Leitsätzen voraus. Von all dem ist allerdings derzeit nichts zu sehen. So kommt in den Handelskonflikt mit China diese Woche sogar etwas Bewegung. Eine US-Delegation unter der Führung des stellvertretenden Handelsbeauftragten Jeffrey Gerrish wird am 7. und 8. Januar mit der Regierung in Peking eine neue Gesprächsrunde eröffnen. In Hinblick auf die Zinsen könnte es sogar zu positiven Überraschungen für die Aktienmärkte kommen. Denn war vor einigen Monaten noch von drei Erhöhungen in 2019 die Rede, ruderte das Fed in ihrer letzten Sitzung im Dezember klar zurück. Den neuen Prognosen zufolge, die auf Einschätzungen der Mitglieder des geldpolitischen Ausschusses FOMC basieren, rechnet die Notenbank 2019 nur mit zwei Zinsanhebungen und im Jahr 2020 dann noch mit einer.

Wer daran glaubt, dass der US-Aktienmarkt 2019 wieder Fahrt aufnehmen wird, kann einen Blick auf den UBS ETT (Symbol: ETSPX) werfen. Damit lässt sich der Leitindex ohne Verwaltungsgebühren ins Portfolio holen. Anfallende Dividenden werden auf Netto-Basis berücksichtigt.*

*Die Konditionen der ETTs werden jährlich überprüft und können mit einer Frist von 13 Monaten nach Bekanntgabe angepasst werden.

Gewinnentwicklung S&P 500

Stand: 28.12.2018; Quelle: Factset; e = erwartet
Bitte beachten Sie, dass vergangene Wertentwicklungen keine Indikationen für künftige Wertentwicklungen sind.

Weitere Blogeinträge:

Fussball, Glühwein und Feiertage

Die Vorweihnachtszeit hält langsam aber sicher Einzug. In mehreren Schweizer Städten, darunter St. Gallen, Basel und Zürich, beginnen am 24. November die Weihnachtsmärkte. Diese beliebten Anlässe bieten eine gute Gelegenheit, um das Jahr Revue passieren zu lassen.

Unterschiedliche Taktgeber

In der vergangenen Woche blieb kein Börsenauge trocken. In der ersten Hälfte dominierten noch die Bären das Geschehen. Auf der einen Seite trieben drohende neue Lockdowns in China den Investoren Sorgenfalten auf die Stirn.

Ein Wechselbad der Gefühle

Gerade einmal 23 Zeilen umfasst das von der US-Notenbank am 2. November 2022 veröffentlichte geldpolitische Statement. Dieser kurze Text reichte, um die Börsen – quer durch die Anlageklassen – in Aufruhr zu versetzen. Während die Aktienkurse an der Wall Street nach unten drehten, wertete der US-Dollar deutlich auf.

USA: Neues Jahr, neues Glück2019-01-07T10:12:41+01:00

Weekly Hits: Idées de placement 2019

KeyInvest Weekly Hits

Vendredi, 21.12.2018

  • Thème 1: Idée de placement 2019 I - Les actions à dividendes
  • Thème 2: Idée de placement 2019 II - Services d’intérêts publics européens

Idée de placement 2019 I
Les actions à dividendes

UBS a présenté son rapport très consulté « Year Ahead » le 6 décembre dernier. En ligne avec la situation actuelle sur les marchés financiers, les perspectives pour 2019 sont intitulées « Points d’inversion ». Dans la publication de 76 pages, les experts du gestionnaire de fortune leader mondial s’intéressent de très près à l’évolution possible durant la nouvelle année. En outre, ils proposent comme à l’accoutumée des recommandations concrètes. Vous trouverez l’intégralité du rapport « Year Ahead » sur ubs.com/cio. Concernant la classe d’actifs actions, notamment des fournisseurs européens de services d’intérêts publics comptent parmi les favoris d’UBS CIO GWM. Découvrez-en davantage en page 3. Par ailleurs, les spécialistes du marché des capitaux considèrent les actions à dividendes comme riches de perspectives. L’Open End PERLES (symbole : SWDIV) sur le Dow Jones Switzerland Select Dividend 15 Index™ permet aux investisseurs d’intégrer des titres à forts dividendes du marché local des actions dans leur portefeuille. Pendant que ce Tracker est sur le marché depuis plus de sept ans, le Open End PERLES (symbole : QIXEUU) sur le QIX Dividenden Europa Index a été lancé mi-2017.

Le Chief Investment Office d’UBS Global Wealth Management (CIO GWM) prévoit un affaiblissement de la croissance économique mondiale de 3.8% en 2018 à 3.6% en 2019. Dans le même temps, la hausse des bénéfices des entreprises se ralentira. Selon CIO GWM, les cours de nombreuses valeurs patrimoniales financières reflètent déjà ces perspectives incertaines. En conséquence, la gestion de fortune UBS débute 2019 avec une surpondération dans les actions mondiales. Dans le même temps, les spécialistes du marché des capitaux conseillent la diversification et les garanties au vu de l’avancée du cycle du marché. « Les investisseurs feront bien de maintenir leurs positions en actions globales tout en se préparant à une forte volatilité sur le marché », souligne Mark Haefele, Chief Investment Officer de CIO GWM. (Source : UBS, communiqué de presse, 06.12.2018)

Les dividendes constituent un argument en faveur de la classe d’actifs que sont les actions. Selon CIO GWM, ceci s’applique en particulier pour la zone euro et la Suisse où les investisseurs se heurtent encore à un environnement de taux bas. Sur le Swiss Performance Index (SPI™), le rendement en dividendes s’établit actuellement à environ 3%. À titre de comparaison, la rémunération des emprunts de la Confédération à 10 ans évolue en-dessous de zéro. La solidité des bilans des entreprises et de leur rentabilité incite en conséquence les analystes à estimer que les distributions seront durables. Dans la mesure où les dividendes pourraient même connaître une évolution plus stable que les résultats, cette approche est riche de perspectives, en particulier en des temps incertains. « Notre stratégie est basée sur la durabilité des dividendes, leur croissance supérieure à la moyenne ainsi qu’un rendement en dividendes relativement attrayant », explique CIO GWM. (Source : UBS, « Year Ahead », 06.12.2018)
Le Dow Jones Switzerland Select Dividend 15 Index™ suit une stratégie qui correspond tout à fait à cette approche. L’indice sonde systématiquement le marché suisse des actions, à la recherche de titres à dividendes intéressants. À ce jour, la méthode a fonctionné: la stratégie de dividendes affiche une nette surperformance par rapport au SMI™ (cf. graphique)¹. Le QIX Dividenden Europe Index dispose d’un historique relativement court. Avec une procédure de sélection en plusieurs étapes pour ce baromètre boursier, outre le rendement en dividendes attendu et historique, la continuité des versements est essentielle.

Opportunités: avec l’Open End PERLES, les investisseurs peuvent mettre en œuvre une stratégie de dividendes en Suisse (symbole : SWDIV) et/ou dans toute l’Europe (symbole : QIXEUU). Les produits reproduisent le Dow Jones Switzerland Select Dividend 15 Index™ et le QIX Dividenden Europe Index dans un rapport de 10 à 1 respectivement de 100 à 1. En ligne avec le calcul d’investissement, les investisseurs profitent des distributions des entreprises comprises dans les sous-jacents respectifs. D’éventuels versements de dividendes sont pris en compte dans le calcul de l’indice.

Risques: les Open End PERLES ne bénéficient d’aucune protection du capital. Il peut y avoir des pertes lorsque l’indice sous-jacent baisse. Il faut également prendre en compte le risque de change, car la monnaie des membres de l’indice peut être différente de celle dans laquelle le certificat présenté est négocié. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur. Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Dow Jones Switzerland Select Dividend 15 Index™ vs. SMI™ Index (5 ans, aux fins d’illustration uniquement, données en %)

En janvier 2018, le Dow Jones Switzerland Select Dividend 15 Index™ a atteint un niveau record absolu. Même si l’indice n’a pu se maintenir à ce niveau, il se distingue par rapport à la comparaison SMI™ sur cinq ans.

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

QIX Dividenden Europa Index vs. Intel vs. STOXX™ Europe 600 Index (depuis le 03.05.2017, aux fins d’illustration uniquement, données en %)

Depuis son lancement, l’indice QIX Dividenden Europa a perdu des plumes dans un environnement de marché morose. Dans ce contexte, la stratégie s’appuyant sur des règles a toutefois obtenu des résultats légèrement meilleurs que le STOXX™ Europe 600 Index.

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

Open End PERLES sur Dow Jones Switzerland Select Dividend 15 Index™

Symbol SWDIV
SVSP Name Tracker Certifikat
SPVSP Code 1300
Sous-jacent Dow Jones Switzerland Select Dividend 15 Index™ Total Return (CHF)
Devise CHF
Rapport de souscription 10:1
Frais de gestion 0.40% p.a.
Participation 100%
Echéance Open End
Émetteur UBS AG, London
Bid/Ask CHF 190.30 / 191.50
 
Termsheet

Open End PERLES sur QIX Dividenden Europa Index (EUR)

Symbol QIXEUU
SVSP Name Tracker Certifikat
SPVSP Code 1300
Sous-jacent QIX Dividenden Europa Net Return Index (EUR)
Devise EUR
Rapport de souscription 100:1
Frais de gestion 1.50% p.a.
Participation 100%
Echéance Open End
Émetteur UBS AG, London
Bid/Ask EUR 91.80 /92.10
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

Apérçu du marché

Index Citation Semaine¹
SMI™ 8’540.16 -3.6%
SLI™ 1’314.35 -3.5%
S&P 500™ 2’506.96 -5.4%
Euro STOXX 50™ 3’051.38 -1.8%
S&P™ BRIC 40 3’748.10 -3.6%
CMCI™ Compos. 871.43 -2.0%
Gold (troy ounce) 1’256.40 USD 0.5%

¹ Changement basé sur le cours de clôture du jour précédent par rapport au cours de clôture de la semaine dernière.

SMI™ vs. VSMI™ 1 année

L’index VSMI™ est calculé depuis 2005. Il affiche la volatilité des actions inclus dans le SMI™ index. Pour la calculation, un portefeuille est utilisé qui ne réagit qu’au variations de la volatilité au lieu des variations des prix. En le faisant, la méthodologie du VSMI™ utilise la volatilité carré, connu sous le terme variance, des options sur le SMI avec 30 jours jusqu’à l’échéance négociées à la Bourse Eurex.

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

Idée de placement 2019 II
Services d’intérêts publics européens

La vision macroéconomique globale pour 2019 présente des zones d’ombre et des zones de lumière. Le secteur des services d’intérêts publics pourrait être relativement insensible à un ralentissement mondial éventuel ainsi qu’aux litiges commerciaux permanents. Déjà au cours de l’année 2018 qui fut pour le moins chaotique, les fournisseurs d’électricité européens ont largement dépassé le marché si l’on se réfère au STOXX™ Europe 600 Utilities Index.¹ UBS CIO GWM reste positif s’agissant de ce secteur : selon les analystes, les évaluations sont intéressantes en comparaison avec d’autres secteurs non cycliques comme les biens de consommation et le secteur de la santé. (Source : UBS CIO GWM, European Utilities, 17.12.2018). Avec un ETT (symbole : ETUTI) sur le STOXX™ Europe 600 Utilities Net Return Index, les investisseurs peuvent littéralement « électriser » leur portefeuille. Le produit se présente actuellement sans commission de gestion courante, et offre par ailleurs un intéressant rendement en dividendes.²

La performance tout à fait positive des services d’intérêts publics européens n’est pas sans fondement : selon des informations de UBS CIO GWM, elle a été portée par des entreprises dont les perspectives de profits bénéficient de la hausse des prix de gros de l’électricité. En 2018, les tarifs ont progressé de 20 à 40% en Europe. Les analystes citent comme bénéficiaires concrets de cette évolution EDF, RWE et Fortum. (Source : UBS CIO GWM, European Utilities, 17.12.2018). À propos de profits, récemment, Iberdrola a également marqué des points dans ce domaine. Au troisième trimestre, le résultat opérationnel a progressé de 34%, dépassant ainsi les attentes du marché. Le fournisseur espagnol de services d’intérêts publics a augmenté de 24% son chiffre d’affaires. Avec une pondération dans l’indice de tout juste 13%, Iberdrola est actuellement le poids lourd du STOXX™ Europe 600 Utilities Index. (Source : STOXX™ Indexfactsheet, 31.10.2018). Toutefois, les experts de UBS CIO GWM ont repéré des risques politiques et réglementaires pour le secteur en 2019, par exemple le Brexit au Royaume-Uni ou de possibles interventions publiques en Italie. Malgré cela, les perspectives de résultats pour les fournisseurs de services d’intérêts publics sont positives, avec un taux de croissance estimé à 6%. (Source : UBS CIO GWM, European Utilities, 17.12.2018)

Opportunités: tous les représentants de la branche mentionnés ici sont membres du STOXX™ Europe 600 Utilities NR Index. Les 28 titres au total font finalement la nique à la faiblesse du marché et suivent une tendance haussière.¹ Avec l’ETT (symbole : ETUTI), il est possible de miser de manière largement diversifiée sur une poursuite de l’évolution positive des cours du secteur « énergétique ». Dans la mesure où le sous-jacent et la variante Net-Return, les dividendes sont réinvestis dans l’indice. Le rendement en distribution actuel s’établit à une valeur élevée de 4,6%.

Risques: il n’existe aucune protection du capital pour le produit présenté. Une évolution négative de l’actif sous-jacent entraîne des pertes correspondantes pour l’ETT. Par ailleurs, avec les produits structurés, l’investisseur supporte le risque d’émetteur. Cela signifie qu’en cas d’insolvabilité d’UBS SA, le capital investi peut être perdu, indépendamment de l’évolution du sous-jacent.

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

STOXX™ Europe 600 Utilities Index vs. STOXX™ Europe 600 Index 5 ans, aux fins d’illustration uniquement, données en %)

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

11.00% p.a. Callable Kick-In GOAL auf Air France-KLM / Delta Air Lines / Lufthansa

Symbol ETUTI
SVSP Name Tracker Certifikat
SPVSP Code 1300
Sous-jacent STOXX™ Europe 600 Utilities Net Return Index
Devise EUR
Rapport de souscription 1:1
Frais de gestion 0.00% p.a.²
Participation 100%
Echéance Open End
Émetteur UBS AG, London
Bid/Ask EUR 826.50 / 831.00
 
Termsheet

Vous trouverez davantage de produits UBS et des informations sur les opportunités et les risques à l’adresse ubs.com/keyinvest.

Source: UBS AG, Bloomberg

Valeurs du: 19.12.2018

¹) La performance passée n’indique pas les résultats futures.
²) Les condition des ETTs sont vérifiés annuellement et peuvent être ajustées avec un délai de 13 mois après la publication.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Idées de placement 20192019-02-15T12:18:29+01:00

Weekly Hits: Investment ideas 2019

KeyInvest Weekly Hits

Friday, 21.12.2018

  • Topic 1: Investment idea 2019 I - Dividend stocks
  • Topic 2: Investment idea 2019 II - European Utilities

Investment idea 2019 I
Dividend stocks

On 6 December UBS published its much-respected report “Year Ahead”. Suitably for the current situation on the financial markets, the 2019 outlook is entitled “Turning Points”. In the 76-page publication the experts at the world’s leading wealth manager take a close look at what might happen in the new year. They also, as usual, make specific recommendations. You can find “Year Ahead” at ubs.com/cio. As far as equities as an asset class are concerned, European utilities are among the favorites of UBS CIO GWM – see page 3. They also think dividend stocks are promising. With the Open End PERLES (symbol: SWDIV) on the Dow Jones Switzerland Select Dividend 15 Index™ investors can gain exposure to high-yielding shares in the domestic market at a single stroke. This tracker certificate has been on the market for over seven years, whereas the Open End PERLES (symbol QIXEUU) on the QIX Dividenden Europa Index was launched in mid-2017.

The Chief Investment Office of UBS Global Wealth Management (CIO GWM) expects global economic growth to weaken from 3.8% in the year now ending to 3.6% in 2019. Corporate earnings will also rise more slowly. CIO GWM feels that the prices of many financial assets already reflect the uncertain prospects. UBS Wealth Management is therefore going in 2019 overweight in global equities. Given the advanced stage of the market cycle, though, they recommend diversification and hedging. “Investors should hold on to their positions in global equities, but be braced for market volatility,” is how Mark Haefele, Chief Investment Officer at CIO GWM, summarizes the outlook. (Source: UBS, press release, 06.12.2018)

One argument in favor of equities as an asset class is the dividends. According to CIO GWM, this is particularly the case for the Eurozone and Switzerland, where investors still face low interest rates. The dividend yield on the Swiss Performance Index (SPI™) is currently around 3%. By way of comparison, 10-year Swiss government bonds yield less than zero. The analysts argue that solid corporate balance sheets and profitability indicate the payouts are sustainable. In fact as dividends might be more stable than profits, they say this approach is especially promising when times are uncertain. “Our strategy is based on dividend sustainability, above-average dividend growth and a relatively attractive dividend yield,” says CIO GWM. (Source: UBS, «Year Ahead», 06.12.2018)
The Dow Jones Switzerland Select Dividend 15 Index™ follows an entirely suitable approach. The benchmark systematically searches the Swiss equity market for attractive dividend stocks. So far the approach has worked: the dividend strategy has clearly outperformed the SMI™ (see chart)¹. The QIX Dividenden Europe Index has a relatively short history. The benchmark has a multi-stage selection process that looks at both expected and historic dividend yields. Steadiness of distributions plays a key role.

Opportunities: With Open End PERLES investors can implement the dividend strategy in Switzerland (Symbol: SWDIV) and/or across Europe (symbol: QIXEUU). The products track the Dow Jones Switzerland Select Dividend 15 Index™ and QIX Dividenden Europe Index at a ratio of 10:1 and 100:1 respectively. In line with the investment theme, investors also benefit from the distributions made by the constituents in the underlying. Any dividend payments are reflected in the index calculation.

Risks: Open End PERLES do not have capital protection. Losses will be made if the underlying index declines. The currency risk must also be taken into account, as the trading currency of some index constituents may differ from the trading currency of the certificate shown. Investors in structured products are also exposed to issuer risk, which means that the capital invested may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Dow Jones Switzerland Select Dividend 15 Index™ vs. SMI™ Index (5 years, for illustrative purposes only, figures in %)

The Dow Jones Switzerland Select Dividend 15 Index™ hit an all-time high in January 2018. Although it was unable to stay at this level, it has beaten the SMI™ over five years.

Source: UBS AG, Bloomberg

As of 19.12.2018

QIX Dividenden Europa Index vs. Intel vs. STOXX™ Europe 600 Index (from 3 May 2017, for illustrative purposes only, figures in %)

The QIX Dividenden Europa Index has fallen in a weak market environment since launch. However, the rule-based strategy did slightly better than the STOXX™ Europe 600.

Source: UBS AG, Bloomberg

As of: 19.12.2018

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

Open End PERLES on Dow Jones Switzerland Select Dividend 15 Index™

Symbol SWDIV
SVSP Name Tracker Certificates
SPVSP Code 1300
Underlying Dow Jones Switzerland Select Dividend 15 Index™ Total Return (CHF)
Currency CHF
Ratio 10:1
Administration fee 0.40% p.a.
Expiry Open End
Participation 100%
Issuer UBS AG, London
Bid/Ask CHF 190.30 / 191.50
 
Termsheet

Open End PERLES on QIX Dividenden Europa Index (EUR)

Symbol QIXEUU
SVSP Name Tracker Certificates
SPVSP Code 1300
Underlying QIX Dividenden Europa Net Return Index (EUR)
Currency EUR
Ratio 100:1
Administration fee 1.50% p.a.
Participation
 100%
Expiry Open End
Issuer UBS AG, London
Bid/Ask EUR 91.80 /92.10
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 19.12.2018

Market overview

Index Quotation Week¹
SMI™ 8’540.16 -3.6%
SLI™ 1’314.35 -3.5%
S&P 500™ 2’506.96 -5.4%
Euro STOXX 50™ 3’051.38 -1.8%
S&P™ BRIC 40 3’748.10 -3.6%
CMCI™ Compos. 871.43 -2.0%
Gold (troy ounce) 1’256.40 USD 0.5%

¹ Change based on the closing price of the previous day compared to the closing price a week ago.

SMI™ vs. VSMI™ 1 year

smi vs vsmi

The VSMI™ Index is calculated since 2005. It shows the volatility of the stocks within the SMI™ index. A portfolio which reacts only to changes in volatility instead of volatility itself is relevant for the calculation. Thereby, the VSMI™ methodology uses the squared volatility, known as variance, of the SMI options with remaining time to expiry of 30 days traded at the Eurex.

Source: UBS AG, Bloomberg

As of: 19.12.2018

Investment idea 2019 II
European Utilities

The macro-economic picture for 2019 has both light and shade. One sector that is relatively insensitive to a possible global slowdown and the ongoing trade disputes is utilities. In a chaotic year on the markets in 2018 European power companies as measured by the STOXX™ Europe 600 Utilities Index clearly outperformed the broad market.¹ UBS CIO GWM is still positive on the sector: the analysts regard valuations as attractive compared to other non-cyclical sectors such as consumer goods and healthcare. (Source: UBS CIO GWM, European Utilities, 17.12.2018) Investors can literally “electrify” their portfolio with an ETT (symbol: ETUTI) on the STOXX™ Europe 600 Utilities Net Return Index. The product currently has no ongoing management fee and also offers an attractive dividend yield.²

There are good reasons why European utilities have done well: according to UBS CIO GWM they have been driven by companies where the profit prospects benefit from rising wholesale electricity prices. In 2018, tariffs were up 20-40% in Europe. The analysts name EDF, RWE and Fortum as specific beneficiaries of this trend. (Source: UBS CIO GWM, European Utilities, 17.12.2018) When it comes to profits, Iberdrola may also score well in this regard. Operating profit was up 34% in Q3, ahead of market expectations. The Spanish utility boosted revenue by 24%. With an weighting of just under 13%, Iberdrola is currently the heavyweight in the STOXX™ Europe 600 Utilities Index. (Source: STOXX™ Index factsheet, 31.10.2018) The experts at UBS CIO GWM see political and regulatory risks for the sector in 2019, such as Brexit and potential government intervention in the sector in Italy. But the profit outlook for utilities is positive, with an estimated growth rate of 6%. (Source: UBS CIO GWM, European Utilities, 17.12.2018)

Opportunities: All the sector companies mentioned so far are constituents of the STOXX™ Europe 600 Utilities NR Index. Recently the 28 stocks in the index have moved up against a weak market environment.¹ With the ETT (symbol: ETUTI) it is possible to back a continuation of the positive price performance in this “energetic” sector. As the underlying in this case is a net return variant, dividends are reinvested in the index. The current distribution yield is an above-average 4.6%.

Risks: This product does not have capital protection. Should the underlying assets deliver a negative performance, the ETT will incur commensurate losses. Investors in structured products are also exposed to issuer risk, which means that the invested capital may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

STOXX™ Europe 600 Utilities Index vs. STOXX™ Europe 600 Index (5 years, for illustrative purposes only, figures in %)

Source: UBS AG, Bloomberg

As of: 19.12.2018

ETT on STOXX™ Europe 600 Utilities Net Return Index

Symbol ETUTI
SVSP Name Tracker Certifikates
SPVSP Code 1300
Underlyings STOXX™ Europe 600 Utilities Net Return Index
Currency EUR
Ratio 1:1
Administration fee 0.00% p.a.²
Participation 100%
Expiry Open End
Issuer UBS AG, London
Bid/Ask EUR 826.50 / 831.00
 
Termsheet

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 19.12.2018

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.
Weekly Hits: Investment ideas 20192019-02-15T12:12:13+01:00
Go to Top